clofibrate has been researched along with Apolipoprotein B-100, Familial Defective in 73 studies
angiokapsul: contains clofibrate & insoitolnicotinate
| Excerpt | Relevance | Reference |
|---|---|---|
| "A patient developed severe hypertriglyceridemia while on treatment with Tamoxifen after a mastectomy and with a statin for a lipid disorder." | 7.70 | Tamoxifen and hypertriglyceridemia. ( Jonkers, GH, 1999) |
| "The effect of a combination of clofibrate and inositol nicotinate (Liporeduct forte, Liporeduct) on lipids and lipoproteins in 20 patients with primary hyperlipoproteinemia (10 type IIa, 7 type IV and 3 tyV) was investigated over a period of 16 weeks." | 7.66 | [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V]. ( Ditschuneit, H; Hutt, V; Klör, HU; Wechsler, JG, 1983) |
| "Probucol was most effective in patients who experienced the greatest decreases in high density lipoprotein (HDL) levels, whereas the cholestyramine-compactin combination worked without decreasing HDL concentrations." | 5.27 | Effects of probucol on xanthomata regression in familial hypercholesterolemia. ( Funahashi, T; Kishino, B; Matsuzawa, Y; Yamamoto, A; Yamamura, T; Yokoyama, S, 1986) |
| "Clofibrate was administered to 5 selected outpatients suffering from type IIa hyperlipoproteinaemia who had previously undergone dietetic treatment, and one female patient suffering from hypo-HDL-aemia in order to elucidate the question as to whether medium long term clofibrate therapy apart from producing an initial increase relative to the LDL concentration may also lead to an absolute increase in the concentration of HDL cholesterol in serum." | 5.26 | [Clofibrate therapy in hypercholesterolemia. Reports on medium-long-term movements of HDL- cholesterol by the action of clofibrate]. ( Mertz, DP, 1980) |
| "A patient developed severe hypertriglyceridemia while on treatment with Tamoxifen after a mastectomy and with a statin for a lipid disorder." | 3.70 | Tamoxifen and hypertriglyceridemia. ( Jonkers, GH, 1999) |
| "The effect of a combination of clofibrate and inositol nicotinate (Liporeduct forte, Liporeduct) on lipids and lipoproteins in 20 patients with primary hyperlipoproteinemia (10 type IIa, 7 type IV and 3 tyV) was investigated over a period of 16 weeks." | 3.66 | [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V]. ( Ditschuneit, H; Hutt, V; Klör, HU; Wechsler, JG, 1983) |
| "Ciprofibrate has the benefit of a long half-life and may also be administered in the form of a single daily dose to patients suffering from major type II hyperlipoproteinaemia." | 2.66 | Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and B. ( Bakir, R; Chanu, B; Djian, F; Goy-Loeper, J; Rouffy, J, 1985) |
| "Colestipol was more effective than clofibrate in lowering the cholesterol fractions associated with increased cardiovascular risk." | 2.65 | Comparative efficacy of colestipol and clofibrate in type IIa hyperlipoproteinemia. ( Heilman, J; Linden, CV; O'Connell, MJ; Vecchio, TJ, 1982) |
| "Probucol has a sustained effect, additive to that of a lipid-lowering diet; it can reduce total serum cholesterol and cause xanthoma regression even in patients with receptor-defective homozygous familial hypercholesterolemia." | 1.27 | Medical management of hyperlipidemia and the role of probucol. ( Davignon, J, 1986) |
| "Probucol was most effective in patients who experienced the greatest decreases in high density lipoprotein (HDL) levels, whereas the cholestyramine-compactin combination worked without decreasing HDL concentrations." | 1.27 | Effects of probucol on xanthomata regression in familial hypercholesterolemia. ( Funahashi, T; Kishino, B; Matsuzawa, Y; Yamamoto, A; Yamamura, T; Yokoyama, S, 1986) |
| "Oral carnitine has been reported to have a lipid-lowering effect with concomitant elevation of high density lipoprotein cholesterol (HDL-C) levels in normo- and hyperlipidemic individuals." | 1.27 | Plasma carnitine and lipid-lowering drugs. ( Davignon, J; Nestruck, AC; Pande, SV, 1985) |
| "Ciprofibrate was convenient to take and was without subjective side effects." | 1.26 | Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia. ( Olsson, AG; Orö, L, 1982) |
| "Treatment with clofibric acid over a long period of time may well give rise to additional reactions through influences exerted upon the insulin level." | 1.26 | [Effect of clofibric acid on fatty acid metabolism in HLP patients in the 2d half of life]. ( Reuter, W, 1982) |
| " All patients were dietary adapted before the preliminary wash-out period of 4 weeks and received etofylline clofibrate in a dosage of 500 mg/day (2x1 capsule) over 4 weeks, and 750 mg/day (3 x 1 capsule) over further 4 months." | 1.26 | [Clinical effects and tolerance of etofylline clofibrate]. ( Metz, G; Specker, M; Ziegler, WJ, 1980) |
| "Fenofibrate was also found to normalize platelet aggregation in patients with type IIb HLP." | 1.26 | [Pharmacology of fenofibrate (author's transl)]. ( Kritchevsky, D, 1980) |
| "Clofibrate treatment was associated with decreases in 11." | 1.26 | Effect of colestipol and clofibrate on plasma lipid and lipoproteins in type IIa hyperlipoproteinemia. ( Crow, LO; Hunninghake, DB; Isaacson, SO; Probstfield, JL, 1981) |
| "One patient with familial hypercholesterolemia (untreated total cholesterol 800 mg%) received a combined drug treatment during 5 years." | 1.26 | Lipids and lipoproteins in hyperlipidemia type IIa during treatment with different lipid lowering drugs. ( Ditschuneit, H; Hutt, V; Klör, HU; Wechsler, JG, 1980) |
| "Bezafibrate is a potent lipid-lowering agent of the new generation." | 1.26 | Clinical experience with bezafibrate. ( Hausmann, L; Kaffarnik, H; Mühlfellner, G; Mühlfellner, O; Schneider, J; Schubotz, R, 1980) |
| "probucol is a new hypolipaemic agent which differs from similar drugs in current use by its chemical structurae and, probably, by its mode of action." | 1.26 | [The effects of probucol in man (author's transl)]. ( Leutenegger, M, 1980) |
| "Clofibrate was administered to 5 selected outpatients suffering from type IIa hyperlipoproteinaemia who had previously undergone dietetic treatment, and one female patient suffering from hypo-HDL-aemia in order to elucidate the question as to whether medium long term clofibrate therapy apart from producing an initial increase relative to the LDL concentration may also lead to an absolute increase in the concentration of HDL cholesterol in serum." | 1.26 | [Clofibrate therapy in hypercholesterolemia. Reports on medium-long-term movements of HDL- cholesterol by the action of clofibrate]. ( Mertz, DP, 1980) |
| "Niceritrol treatment significantly reduced the Chol/TG ratio in VLDL while no such effect was seen during clofibrate administration." | 1.26 | Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease. ( Borberg, J; Gustafsson, IB; Lithell, H; Vessby, B, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 69 (94.52) | 18.7374 |
| 1990's | 4 (5.48) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hazzard, WR | 1 |
| Miller, N | 1 |
| Albers, JJ | 1 |
| Warnick, GR | 1 |
| Baron, P | 1 |
| Lewis, B | 1 |
| Kaffarnik, H | 2 |
| Schneider, J | 2 |
| Schubotz, R | 2 |
| Zöfel, P | 1 |
| Hausmann, L | 2 |
| Goebel, KM | 1 |
| Colman, RW | 1 |
| Stewart, JM | 1 |
| Packard, CJ | 1 |
| Lorimer, AR | 1 |
| Boag, DE | 1 |
| Shepherd, J | 1 |
| Sirtori, M | 1 |
| Montanari, G | 1 |
| Gianfranceschi, G | 1 |
| Malacrida, MG | 1 |
| Battistin, P | 1 |
| Morazzoni, G | 1 |
| Tremoli, E | 1 |
| Colli, S | 1 |
| Maderna, P | 1 |
| Sirtori, CR | 1 |
| Van Niekerk, JL | 1 |
| Hendriks, T | 1 |
| De Boer, HH | 1 |
| Hutt, V | 4 |
| Wechsler, JG | 3 |
| Klör, HU | 4 |
| Ditschuneit, H | 4 |
| Soler, J | 1 |
| Vinzia, C | 1 |
| Gómez, JM | 1 |
| Morató, J | 1 |
| Illingworth, DR | 1 |
| Olsen, GD | 1 |
| Cook, SF | 1 |
| Sexton, GJ | 1 |
| Wendel, HA | 1 |
| Connor, WE | 1 |
| Kawecka-Jaszcz, K | 1 |
| Kocemba, J | 1 |
| Wasowicz, B | 1 |
| Król, W | 1 |
| Schade, RW | 1 |
| Reuter, W | 2 |
| Neuman, MP | 1 |
| Kurlat, MI | 1 |
| Neuman, J | 1 |
| Nash, DT | 1 |
| Carvalho, AC | 1 |
| Lees, RS | 1 |
| Olsson, AG | 1 |
| Orö, L | 1 |
| Kane, JP | 3 |
| Malloy, MJ | 1 |
| Tun, P | 1 |
| Phillips, NR | 1 |
| Freedman, DD | 1 |
| Williams, ML | 1 |
| Rowe, JS | 1 |
| Havel, RJ | 3 |
| Altomonte, L | 2 |
| Mingrone, G | 2 |
| Negrini, A | 1 |
| De Cunto, F | 1 |
| Greco, AV | 2 |
| Kokot, F | 1 |
| Szczechowska, E | 1 |
| Vecchio, TJ | 1 |
| Linden, CV | 1 |
| O'Connell, MJ | 1 |
| Heilman, J | 1 |
| Schwartzkopff, W | 3 |
| Luley, C | 2 |
| Scheffler, W | 2 |
| Lehmann-Leo, W | 1 |
| Schilling, A | 3 |
| Wegscheider, K | 1 |
| Vessby, B | 2 |
| Lithell, H | 2 |
| Ledermann, H | 1 |
| Udelhoven, P | 1 |
| Wirth, A | 1 |
| Middelhoff, G | 1 |
| Braeuning, C | 1 |
| Schlierf, G | 2 |
| Pasquali, R | 1 |
| Melchionda, N | 1 |
| Parenti, M | 1 |
| Cavazzini, MG | 1 |
| Biso, P | 1 |
| Baraldi, G | 1 |
| Sorrenti, G | 1 |
| De Benedittis, G | 1 |
| Labò, G | 1 |
| Ziegler, WJ | 2 |
| Metz, G | 1 |
| Specker, M | 1 |
| Vorberg, G | 1 |
| Ditschuneit, HH | 1 |
| Kritchevsky, D | 1 |
| Spodick, DH | 1 |
| Hunninghake, DB | 4 |
| Probstfield, JL | 2 |
| Crow, LO | 1 |
| Isaacson, SO | 1 |
| Bell, C | 1 |
| Olson, L | 1 |
| Sale, JK | 1 |
| Johnstone, JH | 1 |
| Mühlfellner, G | 1 |
| Mühlfellner, O | 1 |
| Ghirlanda, G | 1 |
| Manna, R | 1 |
| Rebuzzi, A | 1 |
| Pala, MA | 1 |
| Calder, D | 2 |
| Sznajderman, M | 1 |
| Leutenegger, M | 1 |
| Noseda, G | 1 |
| Fragiacomo, C | 1 |
| Weidmann, P | 1 |
| Bachmann, C | 1 |
| Mertz, DP | 3 |
| Crouse, JR | 1 |
| Grundy, SM | 1 |
| Hrebícek, J | 1 |
| Skottová, N | 1 |
| Chmela, Z | 1 |
| Hrbková, M | 1 |
| Rajecová, E | 1 |
| Klimes, I | 1 |
| Seböková, E | 1 |
| Rychnavská, E | 1 |
| Pleváková, L | 1 |
| Linke-Cvrkalová, A | 1 |
| Langrová, H | 1 |
| Farmer, JA | 1 |
| Gotto, AM | 2 |
| Jonkers, GH | 1 |
| Suermann, I | 2 |
| Loewer, H | 2 |
| Gustafsson, IB | 1 |
| Borberg, J | 1 |
| Gustafson, A | 1 |
| Colombo, L | 1 |
| Monarca, A | 1 |
| Goldberg, D | 1 |
| Zanetta, R | 1 |
| Bolzano, K | 1 |
| Krempler, F | 1 |
| Schellenberg, B | 1 |
| Boucherle, A | 1 |
| Calop, J | 1 |
| Rossignol, AM | 1 |
| Bost, M | 1 |
| Peters, JR | 1 |
| Palmer, RH | 1 |
| Rodriguez, F | 1 |
| López, IM | 1 |
| Jover, E | 1 |
| Davignon, J | 2 |
| Tikkanen, MJ | 1 |
| Nikkilä, EA | 1 |
| Jones, PH | 1 |
| Scott, LW | 1 |
| Postiglione, A | 1 |
| Riccardi, G | 1 |
| Saldalamacchia, G | 1 |
| Brown, WV | 1 |
| Yamamoto, A | 1 |
| Matsuzawa, Y | 1 |
| Yokoyama, S | 1 |
| Funahashi, T | 1 |
| Yamamura, T | 1 |
| Kishino, B | 1 |
| West, R | 1 |
| Gibson, P | 1 |
| Lloyd, J | 1 |
| Lin, TL | 1 |
| Peters, J | 1 |
| Lipovetskiĭ, BM | 1 |
| Triufanov, VF | 1 |
| Teriukova, NP | 1 |
| Rouffy, J | 1 |
| Chanu, B | 1 |
| Bakir, R | 1 |
| Djian, F | 1 |
| Goy-Loeper, J | 1 |
| Haberbosch, W | 1 |
| Gnasso, A | 1 |
| Ziegler, W | 1 |
| Augustin, J | 1 |
| Nestruck, AC | 1 |
| Pande, SV | 1 |
8 reviews available for clofibrate and Apolipoprotein B-100, Familial Defective
| Article | Year |
|---|---|
The treatment of familial hypercholesterolaemia by partial ileal bypass surgery. A review of the literature.
Topics: Anticholesteremic Agents; Cholesterol; Clofibrate; Diarrhea; Heterozygote; Homozygote; Humans; Hyper | 1984 |
[Hyperlipoproteinemia type II].
Topics: Adolescent; Adult; Cecum; Child; Cholesterol, Dietary; Cholestyramine Resin; Clofibrate; Coronary Di | 1980 |
Therapy of hyperlipidemic states.
Topics: Cholesterol, Dietary; Cholestyramine Resin; Clofibrate; Colestipol; Dietary Fats; Drug Therapy, Comb | 1982 |
Choosing the right lipid-regulating agent. A guide to selection.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Fenofibrat | 1996 |
Effect of fibric acid derivatives on blood lipid and lipoprotein levels.
Topics: Anticholesteremic Agents; Bezafibrate; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Gemfib | 1987 |
Effects of fibric acid derivatives on biliary lipid composition.
Topics: Bezafibrate; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Feno | 1987 |
Treatment of hypercholesterolemia.
Topics: Animals; Cholestyramine Resin; Clofibrate; Colestipol; Cricetinae; Dogs; Drug Therapy, Combination; | 1986 |
The diagnosis and management of hyperlipidemia.
Topics: Adolescent; Adult; Child; Child, Preschool; Cholesterol; Cholestyramine Resin; Chylomicrons; Clofibr | 1986 |
15 trials available for clofibrate and Apolipoprotein B-100, Familial Defective
| Article | Year |
|---|---|
Clofibrate and tiadenol treatment in hyperlipoproteinemias. A comparative trial of drugs affecting lipoprotein catabolism and biosynthesis.
Topics: Adult; Aged; Blood Glucose; Clinical Trials as Topic; Clofibrate; Fatty Alcohols; Female; Humans; Hy | 1983 |
Ciprofibrate in the therapy of type II hypercholesterolemia. A double-blind trial.
Topics: Adult; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Fibric Aci | 1982 |
[Effect of probucol on serum cholesterol concentration in primary hyperlipoproteinemia].
Topics: Adult; Aged; Cholesterol; Clinical Trials as Topic; Clofibrate; Female; Humans; Hyperlipoproteinemia | 1982 |
Normalization of low-density-lipoprotein levels in heterozygous familial hypercholesterolemia with a combined drug regimen.
Topics: Adult; Aged; Cholesterol; Clinical Trials as Topic; Clofibrate; Colestipol; Drug Therapy, Combinatio | 1981 |
[Double-blind study of the therapeutic activity of a new hypolipemic drug: etofibrate].
Topics: Adult; Aged; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Huma | 1981 |
[Comparison of the lipid-lowering agents clofibrate and bezafibrate in patients with hyperlipoproteinemias IIa and IIb].
Topics: Adult; Bezafibrate; Cholesterol; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind | 1981 |
Comparative efficacy of colestipol and clofibrate in type IIa hyperlipoproteinemia.
Topics: Adolescent; Adult; Aged; Cholesterol; Clofibrate; Colestipol; Drug Evaluation; Female; Humans; Hyper | 1982 |
[Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV].
Topics: Adult; Aged; Anticholesteremic Agents; Bezafibrate; Clofibrate; Clofibric Acid; Female; Fenofibrate; | 1982 |
Treatment of familial hypercholesterolemia with a combination of bezafibrate and guar.
Topics: Adult; Apolipoproteins; Bezafibrate; Body Weight; Cholesterol; Cholesterol, LDL; Clofibrate; Clofibr | 1982 |
[Therapeutic experiences in the treatment of hyperlipoproteinaemia with etofylline clofibrate (author's transl)].
Topics: Clofibrate; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hyperlipoproteinemia | 1980 |
[Effect of etofylline clofibrate on the composition of lipoproteins in hyperlipidaemia type IIb and IV (author's transl)].
Topics: Adult; Aged; Clofibrate; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; | 1980 |
Effects of colestipol, clofibrate, and placebo on plasma lipoproteins of patients with hypercholesterolemia.
Topics: Adult; Aged; Cholesterol; Clofibrate; Colestipol; Female; Humans; Hyperlipoproteinemia Type II; Lipi | 1981 |
Effects of fibric acid derivatives on biliary lipid composition.
Topics: Bezafibrate; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Feno | 1987 |
Hypolipidemic effects of bezafibrate: studies in Italy.
Topics: Bezafibrate; Clinical Trials as Topic; Clofibrate; Double-Blind Method; Humans; Hyperlipoproteinemia | 1986 |
Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and B.
Topics: Adult; Apolipoproteins A; Apolipoproteins B; Clofibrate; Clofibric Acid; Drug Evaluation; Female; Fe | 1985 |
51 other studies available for clofibrate and Apolipoprotein B-100, Familial Defective
| Article | Year |
|---|---|
Association of isoapolipoprotein-E3 deficiency with heterozygous familial hypercholesterolaemia: implications for lipoprotein physiology.
Topics: Apolipoprotein E3; Apolipoproteins; Apolipoproteins E; Child; Clofibrate; Female; Heterozygote; Huma | 1981 |
Long-term treatment of hyperlipoproteinemia with etofibrate: clinical observations.
Topics: Adult; Aged; Cholesterol; Clofibrate; Clofibric Acid; Creatine Kinase; Female; gamma-Glutamyltransfe | 1980 |
The role of platelets in the genesis of ischemia.
Topics: Adenosine Diphosphate; Animals; Arteriosclerosis; Blood Platelets; Cholesterol; Clofibrate; Coronary | 1982 |
Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinaemic subjects.
Topics: Adult; Apolipoproteins; Apolipoproteins B; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, | 1982 |
[Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
Topics: Clofibrate; Drug Combinations; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; H | 1983 |
[Plafibride treatment of hyperlipidemias type II and IV].
Topics: Adult; Cholesterol; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemia Type II; Hyperl | 1984 |
[Effect of combination therapy of clofibric acid and nicotinic acid derivatives on fatty acid metabolism in hyperlipoproteinemia].
Topics: Aged; Clofibrate; Clofibric Acid; Drug Therapy, Combination; Fatty Acids; Female; Humans; Hyperlipop | 1982 |
Elevation of high density lipoprotein cholesterol (cHDL) and reduction of the total cholesterol/cHDL index in the treatment of hyperlipoproteinaemias IIb and IV with bezafibrate.
Topics: Adult; Aged; Bezafibrate; Cholesterol; Cholesterol, HDL; Clofibrate; Clofibric Acid; Female; Humans; | 1983 |
Gemfibrozil--a new lipid lowering agent.
Topics: Cholesterol; Clofibrate; Dose-Response Relationship, Drug; Double-Blind Method; Gemfibrozil; Humans; | 1980 |
Platelets intravascular coagulation and fibrinolysis in hyperlipidaemias: relationship to thrombo-embolic complications.
Topics: Adenine Nucleotides; Adult; Blood Coagulation Disorders; Blood Platelets; Clofibrate; Factor XII; Fi | 1980 |
Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Blood Sedimentation; Body Weight; Cholesterol; Ch | 1982 |
Elevated lipoprotein lipase activity in skeletal muscle tissue during treatment of hypertriglyceridaemic patients with bezafibrate.
Topics: Adipose Tissue; Adult; Bezafibrate; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemia | 1982 |
[Lipid lowering improved? Therapeutic progress by using biological mechanisms].
Topics: Anticholesteremic Agents; Clofibrate; Clofibric Acid; Humans; Hyperlipoproteinemia Type II | 1982 |
[Comparative effect of probucol and clofibrate in patients with primary hypercholesterolemia].
Topics: Adult; Clofibrate; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Male; Middle | 1982 |
[Effect of clofibric acid on fatty acid metabolism in HLP patients in the 2d half of life].
Topics: Adult; Aged; Cholesterol Esters; Clofibrate; Clofibric Acid; Fatty Acids; Female; Humans; Hyperlipop | 1982 |
[Clinical effects and tolerance of etofylline clofibrate].
Topics: Clofibrate; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Hy | 1980 |
[Pharmacology of fenofibrate (author's transl)].
Topics: Animals; Cholesterol; Clofibrate; Dogs; Dose-Response Relationship, Drug; Fenofibrate; Humans; Hyper | 1980 |
Normalization of low-density lipoproteins in familial hypercholesterolemia.
Topics: Clofibrate; Humans; Hyperlipoproteinemia Type II; Lipoproteins, LDL | 1981 |
Effect of colestipol and clofibrate on plasma lipid and lipoproteins in type IIa hyperlipoproteinemia.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Colestipol; Dose-Response Relati | 1981 |
Effect of colestipol and clofibrate, singly and in combination, on plasma lipid and lipoproteins in type IIb hyperlipoproteinemia.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Colestipol; Drug Interactions; D | 1981 |
Pre- and post-treatment values of HDL cholesterol and total: HDL cholesterol ratio in hyperlipoproteinaemic subjects.
Topics: Cholesterol; Cholesterol, HDL; Clofibrate; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipopr | 1981 |
Lipids and lipoproteins in hyperlipidemia type IIa during treatment with different lipid lowering drugs.
Topics: Adolescent; Bezafibrate; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemia Type II; I | 1980 |
Clinical experience with bezafibrate.
Topics: Bezafibrate; Blood Glucose; Body Weight; Cholesterol; Clofibrate; Clofibric Acid; Coronary Disease; | 1980 |
[Bile lipid composition in subjects with blood lipid disorders (types II and IV). Effect of a new hypolipemic drug (Etofibrate)].
Topics: Adult; Aged; Bile; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemia Type II; Hyperli | 1980 |
[Therapy of hyperlipoproteinemia type IIa, IIb and IV with Etofibrate retard].
Topics: Blood Glucose; Cholesterol; Clofibrate; Creatinine; Delayed-Action Preparations; Humans; Hyperlipopr | 1980 |
[Effect of phenofibrate on the blood serum lipid level in hyperlipoproteinemias and its comparison with clofibrate].
Topics: Adult; Aged; Cholesterol; Clofibrate; Female; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hyp | 1980 |
[The effects of probucol in man (author's transl)].
Topics: Anticholesteremic Agents; Arteriosclerosis; Bile; Clofibrate; Electrocardiography; Heart; Humans; Hy | 1980 |
[The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
Topics: Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Humans; Hyperlipoproteinemia Type II; Hyperlip | 1980 |
Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Humans; Hyperlipopro | 1980 |
The effect of etofibrate retard, bezafibrate and procetofen.
Topics: Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Female; Fenofibrate; Humans; Hyperlipopr | 1980 |
[Clofibrate therapy in hypercholesterolemia. Reports on medium-long-term movements of HDL- cholesterol by the action of clofibrate].
Topics: Adult; Bezafibrate; Clofibrate; Clofibric Acid; Drug Administration Schedule; Female; Humans; Hyperc | 1980 |
[Use of etofyllinclofibrate (Duolip Forte) in combined hyperlipidemia].
Topics: Adult; Aged; Clofibrate; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type V; | 1995 |
[Etofylline clofibrate in the treatment of diabetic dyslipidemia: results of a 6-month period of therapy].
Topics: Clofibrate; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoprotei | 1995 |
Tamoxifen and hypertriglyceridemia.
Topics: Anticholesteremic Agents; Antineoplastic Agents, Hormonal; Atorvastatin; Breast Neoplasms; Clofibrat | 1999 |
[Lowering of the lipoproteins in type IIa hyperlipoproteinemia by means of bezafibrate. Comparison with clofibrate].
Topics: Anticholesteremic Agents; Cholesterol; Clofibrate; Drug Evaluation; Humans; Hyperlipoproteinemia Typ | 1979 |
Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease.
Topics: Adult; Aged; Arteriosclerosis; Clofibrate; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipopr | 1979 |
Treatment of hyperlipoproteinemia type II with etofibrate.
Topics: Body Weight; Cholesterol; Clofibrate; Clofibric Acid; Glucose Tolerance Test; Humans; Hyperlipoprote | 1979 |
[Tolerability and side-effects of bis-(hydroxy-2-ethylthio)-1,10-decane (BS 530) as compared with clofibrate in the therapy of hyperlipemia].
Topics: Clofibrate; Fatty Alcohols; Gastrointestinal Diseases; Headache; Humans; Hyperlipidemias; Hyperlipop | 1979 |
[The range and lipid-lowering effect of etofibrate as a retard-preparation in patients with hyperlipoproteinemia type IIa (author's transl)].
Topics: Adult; Aged; Anticholesteremic Agents; Clofibrate; Clofibric Acid; Delayed-Action Preparations; Fema | 1979 |
[A comparison of bezafibrate and clofibrate in type II B and type IV hyperlipoproteinemia].
Topics: Adult; Aged; Bezafibrate; Clofibrate; Clofibric Acid; Dose-Response Relationship, Drug; Female; Huma | 1979 |
[Treatment of essential hypercholesterolemia by normolipidemic drugs in children].
Topics: Adolescent; Child; Child, Preschool; Cholestyramine Resin; Clofibrate; Fenofibrate; Humans; Hydroxym | 1989 |
Plafibride treatment and serum lipids in hyperlipoproteinemias.
Topics: Adolescent; Adult; Blood Glucose; Cholesterol; Clofibrate; Clofibric Acid; Diet; Female; Humans; Hyp | 1987 |
Medical management of hyperlipidemia and the role of probucol.
Topics: Adult; Arteriosclerosis; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Female; Gem | 1986 |
Current pharmacologic treatment of elevated serum cholesterol.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Co | 1987 |
Potential use of fenofibrate and other fibric acid derivatives in the clinic.
Topics: Clofibrate; Fenofibrate; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hy | 1987 |
Effects of probucol on xanthomata regression in familial hypercholesterolemia.
Topics: Achilles Tendon; Adolescent; Adult; Aged; Anticholesteremic Agents; Child; Child, Preschool; Cholest | 1986 |
Treatment of homozygous familial hypercholesterolaemia: an informative sibship.
Topics: Adolescent; Age Factors; Arteriosclerosis; Cholestyramine Resin; Clofibrate; Female; Homozygote; Hum | 1985 |
Carotenoids and vitamin A: the effect of hypocholesterolemic agents on serum levels.
Topics: Adult; Analysis of Variance; Anticholesteremic Agents; Carotenoids; Cellulose; Cholesterol, LDL; Clo | 1985 |
[Differential use of diet and drugs in dyslipoproteinemias].
Topics: Adult; Clofibrate; Dietary Carbohydrates; Dietary Fats; Female; Humans; Hyperlipoproteinemia Type II | 1985 |
The effect of etophylline clofibrate on HDL subfractions.
Topics: Adult; Aged; Apolipoproteins; Cholesterol, LDL; Clofibrate; Female; Heparin; Humans; Hyperlipoprotei | 1985 |
Plasma carnitine and lipid-lowering drugs.
Topics: Carnitine; Cholesterol, HDL; Clofibrate; Female; Humans; Hyperlipidemia, Familial Combined; Hyperlip | 1985 |